Policies and Politics—What’s in Store for Healthcare?

With Joe Biden’s inauguration as the 46th president of the United States and Democrat control of both the house and senate, there are a number of policy changes anticipated. As expected, the current focus of the administration is the pandemic, bolstering the roll-out of the vaccine and providing economic support to those parts of the economy that have been most impacted, but what else? Precision’s Ryan Cox explores some of the expected policy priorities and changes for healthcare in 2021.

M&A in 2020, Implications for 2021

New healthcare policies undoubtedly mean a shift in market access. In this article, Precision’s Dan Danielson explores the high-level potential market consequences in 2 major segments of the US healthcare environment and the rationale behind each: the healthcare systems and hospitals that deliver care, and pharmaceutical manufacturers who develop new drug therapies for the patients served by the health systems.

CMS Physician Fee Schedule (PFS) Creates More Tailwinds for Telehealth and New Opportunities for Pharma

Telehealth vendors, health systems, and clinicians are seeing opportunities to further expand delivery of reimbursable telehealth services since CMS issued its (CY) 2021 Medicare Physician Fee Scale final rule on December 1, 2020. Precision’s Maureen Hennessey discussing the impact of these expanded opportunities, and how they set the stage for amping up the velocity for telehealth growth.

340B Policy Changes and the Ongoing Challenges in 2021

With the new changes in the latest CMS 340B rules and policies regarding patient access to discounted drugs, there will certainly be challenges between pharma and contracted pharmacies. Precision’s Dominic Galante discusses the potential positions that will be taken by plaintiffs, and the associated 340B Program litigation.